Craig-Hallum raises target for Myriad Genetics stock from USD 4.00 to USD 8.00

Published on 10/05/2026 at 19:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 190.70 million in the second quarter of 2026. Myriad Genetics stock costs EUR 4.00 on October 5, 2026 versus EUR 4.03.

MYGN, US62855J1043, Illustration mit AI erstellt.

Myriad Genetics (ISIN US62855J1043) was trading at EUR 4.00 at Lang & Schwarz on October 5, 2026 at 7:00 p.m. CEST, down 0.74 percent versus the prior close of EUR 4.03. According to Yahoo Finance on October 2, 2026, Craig-Hallum maintained its Buy rating and raised the price target from USD 4.00 to USD 8.00.

Craig-Hallum doubles its target

The target revision gives Myriad Genetics a fresh valuation reference after a difficult second quarter, but it remains an analyst view rather than company guidance. The USD 8.00 target is double the previous USD 4.00 level, making the change the clearest current catalyst for the stock.

Second-quarter losses remain material

According to StockTitan, Myriad reported USD 190.70 million in second-quarter 2026 revenue, down 11.00 percent year over year, and a USD 43.20 million net loss, or USD 0.46 per share.

The same filing summary shows adjusted gross margin at 66.60 percent and adjusted EBITDA at negative USD 16.90 million for the second quarter. Myriad guided full-year 2026 revenue to USD 770.00 million to USD 790.00 million and adjusted gross margin to 66.00 percent to 67.00 percent.

Nasdaq range frames the valuation

Myriad's market capitalization was USD 424.1 million on October 5, 2026, while the Nasdaq 52-week range stood at USD 2.74 to USD 8.59. The current euro quote therefore sits alongside a wide USD trading history and a business still reporting operating losses.

For additional exchange context, the Nasdaq quote was last at USD 4.49 at 1:00 p.m. ET on October 5, 2026, versus a previous USD 4.54 close. Myriad operates in healthcare and diagnostics, developing molecular tests for oncology, women's health and pharmacogenomics.

Stock trades after the Xetra close

Lang & Schwarz showed Myriad Genetics stock at EUR 4.00 on October 5, 2026 at 7:00 p.m. CEST, down 0.74 percent against the EUR 4.03 prior close. The quote was in the after-hours phase for the German market perspective.